-
Something wrong with this record ?
Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale
NC. Cross, HE. White, T. Ernst, L. Welden, C. Dietz, G. Saglio, FX. Mahon, CC. Wong, D. Zheng, S. Wong, SS. Wang, S. Akiki, F. Albano, H. Andrikovics, J. Anwar, G. Balatzenko, I. Bendit, J. Beveridge, N. Boeckx, N. Cerveira, SM. Cheng, D....
Language English Country England, Great Britain
Document type Journal Article
NLK
ProQuest Central
from 2000-01-01 to 1 year ago
Open Access Digital Library
from 1997-01-01
Nursing & Allied Health Database (ProQuest)
from 2000-01-01 to 1 year ago
Health & Medicine (ProQuest)
from 2000-01-01 to 1 year ago
Public Health Database (ProQuest)
from 2000-01-01 to 1 year ago
PubMed
27109508
DOI
10.1038/leu.2016.90
Knihovny.cz E-resources
- MeSH
- Fusion Proteins, bcr-abl analysis standards MeSH
- Genes, abl MeSH
- Calibration MeSH
- Humans MeSH
- Polymerase Chain Reaction MeSH
- Proto-Oncogene Proteins c-bcr genetics MeSH
- Reference Standards MeSH
- World Health Organization MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
Molecular monitoring of chronic myeloid leukemia patients using robust BCR-ABL1 tests standardized to the International Scale (IS) is key to proper disease management, especially when treatment cessation is considered. Most laboratories currently use a time-consuming sample exchange process with reference laboratories for IS calibration. A World Health Organization (WHO) BCR-ABL1 reference panel was developed (MR(1)-MR(4)), but access to the material is limited. In this study, we describe the development of the first cell-based secondary reference panel that is traceable to and faithfully replicates the WHO panel, with an additional MR(4.5) level. The secondary panel was calibrated to IS using digital PCR with ABL1, BCR and GUSB as reference genes and evaluated by 44 laboratories worldwide. Interestingly, we found that >40% of BCR-ABL1 assays showed signs of inadequate optimization such as poor linearity and suboptimal PCR efficiency. Nonetheless, when optimized sample inputs were used, >60% demonstrated satisfactory IS accuracy, precision and/or MR(4.5) sensitivity, and 58% obtained IS conversion factors from the secondary reference concordant with their current values. Correlation analysis indicated no significant alterations in %BCR-ABL1 results caused by different assay configurations. More assays achieved good precision and/or sensitivity than IS accuracy, indicating the need for better IS calibration mechanisms.
3 Medizinische Klinik Medizinische Fakultät Mannheim Universität Heidelberg Mannheim Germany
Bergonie Institute Cancer Center Bordeaux INSERM U1218 University of Bordeaux Bordeaux France
Bristol Genetics Laboratory Bristol UK
Chair and Department of Hematology Jagiellonian University Kraków Poland
Clinique de Genetique Oncologique Service de genetique Hopital Erasme Brussels Belgium
Departement de Biopathologie Institut Paoli Calmettes Marseille France
Department of Genetics Portuguese Oncology Institute Porto Portugal
Department of Hematology and Oncology Quest Diagnostics Nichols Institute San Juan Capistrano CA USA
Department of Hematology Oncology Universitätsklinikum Jena Jena Germany
Department of Hematology University of Bari Bari Italy
Department of Molecular Genetics Institute of Hematology and Blood Transfusion Prague Czech Republic
Department of Surgical Pathology Zealand University Hospital Roskilde Denmark
Division of Molecular Microbiology Children's Cancer Research Institute Vienna Austria
Fred Hutchinson Cancer Research Center Seattle WA USA
Hematopathology Unit Hospital Clinic IDIBAPS Barcelona Spain
HMDS Leeds Teaching Hospitals Leeds UK
Imperial Molecular Pathology Hammersmith Hospital London UK
King's College Hospital London London UK
Laboratorio de Biologia Tumoral Disciplina de Hematologia do HC FMUSP São Paulo Brazil
Laboratory of Molecular Pathology Oslo University Hospital Oslo Norway
MLL Munich Leukemia Laboratory Munich Germany
National Specialized Hospital for Active Treatment of Hematological Diseases Sofia Bulgaria
Novartis Pharmaceuticals Corporation East Hanover NJ USA
Pathology Department University Clinical Center Tuzla Tuzla Bosnia and Herzegovina
PathWest Laboratory Medicine WA Department of Haematology Fiona Stanley Hospital Perth WA Australia
Peking University People's Hospital Peking University Institute of Hematology Beijing China
Seoul St Mary's Hospital Leukemia Research Institute The Catholic University of Korea Seoul Korea
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17031776
- 003
- CZ-PrNML
- 005
- 20171025115613.0
- 007
- ta
- 008
- 171025s2016 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/leu.2016.90 $2 doi
- 035 __
- $a (PubMed)27109508
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Cross, N C P $u Wessex Regional Genetics Laboratory, Salisbury NHS Foundation Trust, Salisbury, UK. Faculty of Medicine, University of Southampton, Southampton, UK.
- 245 10
- $a Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale / $c NC. Cross, HE. White, T. Ernst, L. Welden, C. Dietz, G. Saglio, FX. Mahon, CC. Wong, D. Zheng, S. Wong, SS. Wang, S. Akiki, F. Albano, H. Andrikovics, J. Anwar, G. Balatzenko, I. Bendit, J. Beveridge, N. Boeckx, N. Cerveira, SM. Cheng, D. Colomer, S. Czurda, F. Daraio, S. Dulucq, L. Eggen, H. El Housni, G. Gerrard, M. Gniot, B. Izzo, D. Jacquin, JJ. Janssen, S. Jeromin, T. Jurcek, DW. Kim, K. Machova-Polakova, J. Martinez-Lopez, M. McBean, S. Mesanovic, G. Mitterbauer-Hohendanner, H. Mobtaker, MJ. Mozziconacci, T. Pajič, N. Pallisgaard, P. Panagiotidis, RD. Press, YZ. Qin, J. Radich, T. Sacha, T. Touloumenidou, P. Waits, E. Wilkinson, R. Zadro, MC. Müller, A. Hochhaus, S. Branford,
- 520 9_
- $a Molecular monitoring of chronic myeloid leukemia patients using robust BCR-ABL1 tests standardized to the International Scale (IS) is key to proper disease management, especially when treatment cessation is considered. Most laboratories currently use a time-consuming sample exchange process with reference laboratories for IS calibration. A World Health Organization (WHO) BCR-ABL1 reference panel was developed (MR(1)-MR(4)), but access to the material is limited. In this study, we describe the development of the first cell-based secondary reference panel that is traceable to and faithfully replicates the WHO panel, with an additional MR(4.5) level. The secondary panel was calibrated to IS using digital PCR with ABL1, BCR and GUSB as reference genes and evaluated by 44 laboratories worldwide. Interestingly, we found that >40% of BCR-ABL1 assays showed signs of inadequate optimization such as poor linearity and suboptimal PCR efficiency. Nonetheless, when optimized sample inputs were used, >60% demonstrated satisfactory IS accuracy, precision and/or MR(4.5) sensitivity, and 58% obtained IS conversion factors from the secondary reference concordant with their current values. Correlation analysis indicated no significant alterations in %BCR-ABL1 results caused by different assay configurations. More assays achieved good precision and/or sensitivity than IS accuracy, indicating the need for better IS calibration mechanisms.
- 650 _2
- $a kalibrace $7 D002138
- 650 _2
- $a bcr-abl fúzní proteiny $x analýza $x normy $7 D016044
- 650 _2
- $a geny abl $7 D016313
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a polymerázová řetězová reakce $7 D016133
- 650 _2
- $a protoonkogenní proteiny c-bcr $x genetika $7 D051562
- 650 _2
- $a referenční standardy $7 D012015
- 650 _2
- $a Světová zdravotnická organizace $7 D014944
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a White, H E $u Wessex Regional Genetics Laboratory, Salisbury NHS Foundation Trust, Salisbury, UK. Faculty of Medicine, University of Southampton, Southampton, UK.
- 700 1_
- $a Ernst, T $u Department of Hematology/Oncology, Universitätsklinikum Jena, Jena, Germany.
- 700 1_
- $a Welden, L $u Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, SA, Australia.
- 700 1_
- $a Dietz, C $u III. Medizinische Klinik, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Germany.
- 700 1_
- $a Saglio, G $u Department of Clinical and Biological Sciences, San Luigi Hospital, University of Turin, Orbassano, Italy.
- 700 1_
- $a Mahon, F-X $u Bergonie Institute Cancer Center Bordeaux, INSERM U1218, University of Bordeaux, Bordeaux, France.
- 700 1_
- $a Wong, C C $u Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
- 700 1_
- $a Zheng, D $u Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
- 700 1_
- $a Wong, S $u Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
- 700 1_
- $a Wang, S-S $u Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
- 700 1_
- $a Akiki, S $u West Midlands Regional Genetics Laboratory, Birmingham, UK. $7 gn_A_00002926
- 700 1_
- $a Albano, F $u Department of Hematology, University of Bari, Bari, Italy. $7 gn_A_00003380
- 700 1_
- $a Andrikovics, H $u Laboratory of Molecular Diagnostics, Hungarian National Blood Transfusion Service, Budapest, Hungary. Department of Pathophysiology, Semmelweis University, Budapest, Hungary. $7 gn_A_00006665
- 700 1_
- $a Anwar, J $u King's College Hospital London, London, UK. $7 gn_A_00007630
- 700 1_
- $a Balatzenko, G $u National Specialized Hospital for Active Treatment of Hematological Diseases, Sofia, Bulgaria.
- 700 1_
- $a Bendit, I $u Laboratorio de Biologia Tumoral, Disciplina de Hematologia do HC-FMUSP, São Paulo, Brazil.
- 700 1_
- $a Beveridge, J $u PathWest Laboratory Medicine WA, Department of Haematology, Fiona Stanley Hospital, Perth, WA, Australia.
- 700 1_
- $a Boeckx, N $u Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium. Department of Oncology, KUL, Leuven, Belgium.
- 700 1_
- $a Cerveira, N $u Department of Genetics, Portuguese Oncology Institute, Porto, Portugal.
- 700 1_
- $a Cheng, S-M $u Department of Hematology and Oncology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, USA.
- 700 1_
- $a Colomer, D $u Hematopathology Unit, Hospital Clinic, IDIBAPS, Barcelona, Spain.
- 700 1_
- $a Czurda, S $u Division of Molecular Microbiology, Children's Cancer Research Institute, Vienna, Austria.
- 700 1_
- $a Daraio, F $u Department of Clinical and Biological Sciences, San Luigi Hospital, University of Turin, Orbassano, Italy.
- 700 1_
- $a Dulucq, S $u Laboratoire Hematologie, Centre Hospitalier Universitaire de Bordeaux, Universite Bordeaux, Bordeaux, France.
- 700 1_
- $a Eggen, L $u Laboratory of Molecular Pathology, Oslo University Hospital, Oslo, Norway.
- 700 1_
- $a El Housni, H $u Clinique de Genetique Oncologique-Service de genetique, Hopital Erasme, Brussels, Belgium.
- 700 1_
- $a Gerrard, G $u Imperial Molecular Pathology, Hammersmith Hospital, London, UK.
- 700 1_
- $a Gniot, M $u Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland.
- 700 1_
- $a Izzo, B $u Department of Clinical Medicine and Surgery, University 'Federico II' of Naples, Naples, Italy. CEINGE - Biotecnologie Avanzate, Naples, Italy.
- 700 1_
- $a Jacquin, D $u Genoptix, Inc., Carlsbad, CA, USA.
- 700 1_
- $a Janssen, J J W M $u Department of Hematology and Molecular Diagnostics, VU University Medical Center, Amsterdam, The Netherlands.
- 700 1_
- $a Jeromin, S $u MLL Munich Leukemia Laboratory, Munich, Germany.
- 700 1_
- $a Jurcek, T $u Center of Molecular Biology and Gene Therapy, Department of Internal Medicine-Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic.
- 700 1_
- $a Kim, D-W $u Seoul St Mary's Hospital, Leukemia Research Institute, The Catholic University of Korea, Seoul, Korea.
- 700 1_
- $a Machova-Polakova, K $u Department of Molecular Genetics, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
- 700 1_
- $a Martinez-Lopez, J $u Department of Hematology, Hospital Universitario 12 de Octubre, Universidad Complutense, CNIO, Madrid, Spain.
- 700 1_
- $a McBean, M $u Division of Cancer Medicine, Department of Pathology, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia.
- 700 1_
- $a Mesanovic, S $u Pathology Department, University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina.
- 700 1_
- $a Mitterbauer-Hohendanner, G $u Department of Laboratory Medicine, Division of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna, Vienna, Austria.
- 700 1_
- $a Mobtaker, H $u Genoptix, Inc., Carlsbad, CA, USA.
- 700 1_
- $a Mozziconacci, M-J $u Departement de Biopathologie, Institut Paoli-Calmettes, Marseille, France.
- 700 1_
- $a Pajič, T $u Specialized Haematology Laboratory, Department of Haematology, University Medical Centre Ljubljana, Ljubljana, Slovenia.
- 700 1_
- $a Pallisgaard, N $u Department of Surgical Pathology, Zealand University Hospital, Roskilde, Denmark.
- 700 1_
- $a Panagiotidis, P $u Hematology Unit, First Department of Internal Medicine, Laiko Hospital, University of Athens, Athens, Greece.
- 700 1_
- $a Press, R D $u Department of Pathology and Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
- 700 1_
- $a Qin, Y-Z $u Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
- 700 1_
- $a Radich, J $u Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
- 700 1_
- $a Sacha, T $u Chair and Department of Hematology, Jagiellonian University, Kraków, Poland.
- 700 1_
- $a Touloumenidou, T $u Laboratory of Molecular Biology, Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece.
- 700 1_
- $a Waits, P $u Bristol Genetics Laboratory, Bristol, UK.
- 700 1_
- $a Wilkinson, E $u HMDS, Leeds Teaching Hospitals, Leeds, UK.
- 700 1_
- $a Zadro, R $u Faculty of Pharmacy and Biochemistry and University Hospital Center Zagreb, University of Zagreb, Zagreb, Croatia.
- 700 1_
- $a Müller, M C $u III. Medizinische Klinik, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Germany.
- 700 1_
- $a Hochhaus, A $u Department of Hematology/Oncology, Universitätsklinikum Jena, Jena, Germany.
- 700 1_
- $a Branford, S $u Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, SA, Australia. School of Pharmacy and Medical Science, University of South Australia, Adelaide, SA, Australia. School of Medicine, University of Adelaide, SA, Adelaide, Australia. School of Molecular and Biomedical Science, University of Adelaide, Adelaide, SA, Australia.
- 773 0_
- $w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 30, č. 9 (2016), s. 1844-52
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27109508 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20171025 $b ABA008
- 991 __
- $a 20171025115654 $b ABA008
- 999 __
- $a ok $b bmc $g 1255369 $s 992803
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 30 $c 9 $d 1844-52 $e 20160425 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138
- LZP __
- $a Pubmed-20171025
